CD8A and neoplasm: Analysis of tumor growth curves revealed that TRAIL-deficiency indeed affected the anti-tumor efficacy of CY (Figure 6B, P<0.005), suggesting that TRAIL could be an important effector molecule for anti-tumor CD8 T cells.